Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity Rachael Ingram, Heather Kang, Stafford Lightman, David E. Jane, Zuner A. Bortolotto, Graham L. Collingridge, David Lodge, Arturas Volianskis Neuropharmacology, 2018, 142, 30e40 https://doi.org/10.1016/j.neuropharm.2018.06.008 Abstract Ketamine, a channel blocking NMDA receptor antagonist, is used off-label for its psychedelic effects, which may arise from a combination of several inter-related actions. Firstly, reductions of the contribution of NMDA receptors to afferent information from external and internal sensory inputs may distort sensations and their processing in higher brain centres. Secondly, reductions of NMDA receptormediated excitation of GABAergic interneurons can result in [...]
Lire la suiteKetamine Promising in Cocaine Addiction Batya Swift Yasgur, MA, LSW American Journal of Psychiatry, July 05, 2019 https://doi.org/10.1176/appi.ajp.2019.18101123 A single ketamine infusion combined with mindfulness-based relapse prevention therapy (MBRP) improves abstinence and cuts cravings in cocaine-dependent adults, new research suggests. Results of a randomized control trial show that rates of abstinence were significiantly higher in patients who received ketamine plus MBRP compared to control patients. Moreover, those in the group that received ketamine were significantly less likely to experience relapse compared to control persons, and cravings were also significantly lower in the ketamine group throughout the trial. "In individuals receiving MBRP, a single ketamine infusion led to significantly greater [...]
Lire la suiteKetamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression D. Jeffrey Newport, M.D., M.S., M.Div., Linda L. Carpenter, M.D., William M. McDonald, M.D., James B. Potash, M.D., M.P.H., Mauricio Tohen, M.D., Dr.P.H., M.B.A., Charles B. Nemeroff, M.D., Ph.D., The APA Council of Research Task Force on Novel Biomarkers and Treatments American Journal of Psychiatry, 2015, 172, 950–966 doi: 10.1176/appi.ajp.2015.15040465 Objective : The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method : Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials [...]
Lire la suiteCurrent perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions Albert Garcia-Romeu and William A. Richards Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA INTERNATIONAL REVIEW OF PSYCHIATRY, 2018 https://doi.org/10.1080/09540261.2018.1486289 ABSTRACT Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment [...]
Lire la suite